CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 121 enrolled
Drug / intervention
Fluviral™biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01878825
NCT01878825Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older

GlaxoSmithKline·interventional·Posted Jun 17, 2013·Updated Sep 7, 2018

In Brief

A Phase 3 clinical trial evaluating Fluviral™ for Influenza. Completed, enrolled 121 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of Fluviral™ containing the influenza strains recommended for the 2013-2014 season in adults aged 18 years and older.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 17, 2013
Enrollment StartJul 18, 2013
Primary CompletionAug 9, 2013
TodayJul 2, 2026
Enrollment to primary: 21 daysPosted 13.0 years ago

Interventions

Fluviral™biological

1 dose administered intramuscularly in deltoid region of non-dominant arm.